Yousaf Ali, MBBS
- ASSOCIATE PROFESSOR | Medicine, Rheumatology
Specialties:Rheumatology, Internal Medicine
Dr. Ali is a graduate of the Royal Free Hospital School of Medicine in London. After 2 years of postgraduate training in the UK he moved to the US and completed Internal Medicine training at OHSU in Portland, Oregon. He then trained in Rheumatology at Yale University and is board certified in both Rheumatology and Internal Medicine. He is the current Vice Chair of Faculty Affairs in the Department of Medicine. Dr. Ali was in practice in Providence, Rhode Island for 9 years where he was an Assistant Clinical Professor of Medicine at Brown University. He received many awards including the prestigious Beckwith Family award for outstanding teaching.
He has published many articles, book chapters, and has lectured widely on Rheumatoid arthritis, Osteoporosis, Gout, SLE, Osteoarthritis and the development and study of Novel Biologic therapeutics.
American Board of Internal Medicine
- Ankylosing Spondylitis
- Behcet's Disease
- Polymyalgia Rheumatica And Giant Cell Arteritis
- Reiter's Syndrome
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Systemic Lupus Erythematosus
- Temporal Arteritis
- Wegener's Granulomatosis
BM, Royal Free Hospital Sch of Medicine
MD, Royal Free Hospital School of Medicine. University of London
Fellowship, Yale University
Residency, Internal Medicine, Oregon Health Sciences University
Fellowship, Rheumatology, * Yale University School of Medicine *
Best Doctors in Rhode Island
Beckwith Family Award for outstanding teaching
Teaching Recognition Award
Top Doctors in New York
Dr Ali is currently PI on several trials investigating new treatments for SLE and RA. He is also developing a patient centric app to predict flares in RA that should improve care and outcome.
Embrace Study: phase 3/4, multi-center, randomized, double-blind, placebo-controlled,52-week study to evaluate the efficacy and safety of belimumab (HGS1006) in adult subjects of black race with SLE
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti-TNF Therapy
- A Phase 3/4 Multi-Center Randomized Double-Blind Placebo Controlled 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE)
The purpose of this study is to find out if Belimumab is effective and safe in treating patients of black race who have lupus and are receiving other lupus medicines. Lupus occurs more frequently in people of black race and when it does occur it is often more severe....
Hyaluronan Injections for Osteoarthritis of the Knee [review]. Med Lett Drugs Ther.; 40(1030).
Refractory Scleritis Associated with Hepatitis C and Cyroglobulinemia. J Clinical Rheumatology 1999 December;.
Acute pseudogout following intr-articular injection of high molecular weight hyaluronic acid. Am J Med 1999 December ; 107(6): 641-642.
Infliximab induced SLE. Annals Internal Medicine 2002 October; 137(7): 625-626.
Always trust your gut feeling. The Lancet 2005 March; 365(9465): 1201.
Ali Y, Perlman E. Successful treatment of refractory sarcoid associated uveitis with Inflixmab. Annals of Internal Medicine 2004 June; 140(3465): no.11 W-48.
Ali . Self Assessment Questions in Rheumatology . Humana Press;.
Evaluation of the patient with Musculoskeletal symptoms. In: Hand Surgery. LWW Book; pp625-628.
Gout and Pseudogout: Primary Care for Women. Lippincott Williams & Wilkins 2nd Edition; pp633-636.
Aaron RK, Voisinet A, Racine J, Ali Y, Feller ER. Corticosteroid-associated avascular necrosis: dose relationships and early diagnosis. Annals of the New York Academy of Sciences 2011 Dec; 1240.
Bartov JB, Ali Y. Successful use of the interleukin 1 antagonist, anakinra, in a patient with gout, chronic kidney disease, and aplastic anemia. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2013 Dec; 19(8).